vipph legit

vipph legit

Global Industrial Floor Coating Market Set For 6.6% Growth, Reaching $7.63 Billion By 2028

Rams don't dominate, but they're rolling toward the playoffs with superb complementary footballUnretired two-time Pro Bowl LB Shaquil Barrett signs to resume career with Tampa Bay Buccaneers

MOSCOW — Russian President Vladimir Putin on Saturday apologized to his Azerbaijani counterpart for what he called a "tragic incident" following the crash of an Azerbaijani airliner in Kazakhstan that killed 38 people, but stopped short of acknowledging that Moscow was responsible. Putin's apology came as allegations mounted that Russian air defenses shot down the plane while attempting to deflect a Ukrainian drone strike near Grozny, the regional capital of the Russian republic of Chechnya. Russian President Vladimir Putin chairs a Security Council meeting via videoconference Saturday at the Kremlin in Moscow, Russia. An official Kremlin statement issued Saturday said that air defense systems were firing near Grozny airport as the airliner "repeatedly" attempted to land there on Wednesday. It did not explicitly say one of these hit the plane. The statement said Putin apologized to Azerbaijani President Ilham Aliyev "for the fact that the tragic incident occurred in Russian airspace." The readout said Russia has launched a criminal probe into the incident, and Azerbaijani state prosecutors have arrived in Grozny to participate. The Kremlin also said that "relevant services" from Russia, Azerbaijan and Kazakhstan are jointly investigating the crash site near the city of Aktau in Kazakhstan. The plane was flying from Azerbaijan's capital, Baku, to Grozny when it turned toward Kazakhstan, hundreds of miles across the Caspian Sea from its intended destination, and crashed while attempting to land. There were 29 survivors. According to a readout of the call provided by Aliyev's press office, the Azerbaijani president told Putin that the plane was subject to "external physical and technical interference," though he also stopped short of blaming Russian air defenses. Part of an Azerbaijan Airlines plane lies on the ground Thursday near the airport of Aktau, Kazakhstan. Aliyev noted the plane had holes in its fuselage and the occupants sustained injuries "due to foreign particles penetrating the cabin mid-flight." He said that a team of international experts began a probe of the incident at Azerbaijan's initiative, but provided no details. Earlier this week, the Azerbaijani Prosecutor General's office confirmed that investigators from Azerbaijan are working in Grozny. On Friday, a U.S. official and an Azerbaijani minister made separate statements blaming the crash on an external weapon, echoing those made by aviation experts who blamed the crash on Russian air defense systems responding to a Ukrainian attack. U.S. President Joe Biden, responding Saturday to a reporter asking whether he thought Putin should take responsibility for the crash, said: "Apparently he did but I haven't spoken to him." Biden made the comment after leaving church in St. Croix, U.S. Virgin Islands. Passengers and crew members who survived the crash told Azerbaijani media they heard loud noises on the aircraft as it circled over Grozny. Dmitry Yadrov, head of Russia's civil aviation authority Rosaviatsia, said Friday that as the plane was preparing to land in Grozny in deep fog, Ukrainian drones were targeting the city, prompting authorities to close the area to air traffic. Yadrov said after the captain made two unsuccessful attempts to land, he was offered other airports but decided to fly to Aktau. People attend a funeral Saturday for Mahammadali Eganov, who died in the Azerbaijan Airlines Embraer 190 crash near the Kazakhstan's airport of Aktau at the age of 13, in Baku, Azerbaijan. Earlier this past week, Rosaviatsia cited unspecified early evidence as showing that a bird strike led to an emergency on board. In the days following the crash, Azerbaijan Airlines blamed "physical and technical interference" and announced the suspension of flights to several Russian airports. It didn't say where the interference came from or provide any further details. If proven that the plane crashed after being hit by Russian fire, it would be the second deadly civil aviation accident linked to fighting in Ukraine. Malaysia Airlines Flight 17 was downed with a Russian surface-to-air missile, killing all 298 people aboard, as it flew over the area in eastern Ukraine controlled by Moscow-backed separatists in 2014. Russia denied responsibility but a Dutch court in 2022 convicted two Russians and a pro-Russia Ukrainian man for their role in downing the plane with an air defense system brought into Ukraine from a Russian military base. The grave of Mahammadali Eganov, 13, who died in the Azerbaijan Airlines Embraer 190 crash near the Kazakhstan's Aktau airport, is seen Saturday in Baku, Azerbaijan. Following Wednesday's suspension of flights from Baku to Grozny and nearby Makhachkala, Azerbaijan Airlines announced Friday that it would also halt service to eight more Russian cities. Several other airlines made similar announcements since the crash. Kazakhstan's Qazaq Air on Friday said it would stop flying from Astana to the Russian city of Yekaterinburg in the Ural Mountains for a month. Turkmenistan Airlines, the Central Asian country's flagship carrier, on Saturday halted flights to Moscow for at least a month, citing safety concerns. Earlier this past week, Israel's El Al carrier suspended service from Tel Aviv to the Russian capital, citing "developments in Russia's airspace." Stay up-to-date on the latest in local and national government and political topics with our newsletter.Luigi Mangione pleads not guilty to murder and weapons charges in UnitedHealthcare CEO's death

Qatar tribune Lisa Jarvis In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock price to fall by as much as 29%. Yes, fall. For anyone not closely following the heated race for obesity drug dominance (there must be a few of you left?), it might look like we’re living in the upside-down. After all, if these same data were unveiled just three years ago, the market reaction would have been wildly different. The stock might have gone up and headlines would have heralded an advance in the fight against obesity. But we’re in a new era of obesity medicine. The bar for success, once quite modest, has quickly gotten extraordinarily high — especially so for CagriSema. Let me explain. Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its collection of GLP-1 drugs is likely to become the most lucrative franchise in the industry next year), CagriSema was seen as essential for continued growth in 2030 and beyond. And the study results suggest it might not be the contender investors had hoped for. CagriSema is a combination of the GLP-1 agonist semaglutide, the ingredient found in Novo’s Ozempic and Wegovy, and cagrilintide, which mimics two hormones, amylin and calcitonin, that also help control feelings of satiety. So far, we only have top-line results rather than an in-depth analysis provided by a peer-reviewed journal article. But the headline is that CagriSema allowed people to lose 20.4% of their body weight on average — better than Wegovy, but about on par with what people can already achieve with Eli Lilly’s Zepbound. And the results fell below the 25% target Novo itself had dangled before investors as the trial’s likely outcome. Another reason investors reacted with such negativity is that the limited data suggests side effects might be hampering the drug’s full potential. The 68-week study gave participants the flexibility to control the dosage of the drug, and among those who were taking a higher dose by the end of the study, average weight loss was nearly 23%. But just 57% of participants stuck with the highest dose, leading investors to assume many took a step back to help manage common gastrointestinal side effects. (Though, to be clear, that’s still a guess — we need the full data to know for sure.) Meanwhile, people enrolled in the study who were given either semaglutide or cagrilintide alone were more likely to tolerate that higher dose. Cagrisema is one of a wave of treatments in development that each take a different twist on mimicking naturally occurring hormones that control blood sugar and a feeling of fullness. Companies are exploring different combinations of hormones, as well as differing approaches to tuning their activity. Each study on a new combination is intensely scrutinized to try to determine the best way forward in obesity medicine. And it’s not only about which causes the most weight loss. It’s also about controlling other health indicators, whether that’s blood sugar control or improved cholesterol levels. After Novo’s perceived stumble, stocks for companies developing alternatives, like Amgen, Viking Therapeutics and Structure Therapeutics, all saw modest gains. Lilly has been the biggest beneficiary from Novo’s disappointment. But then, it already had the upper hand. Earlier this month, Lilly said that Zepbound handily beat Wegovy in a head-to-head trial of the two drugs, with its drug offering 20% weight loss compared with Wegovy’s 14%. And CagriSema’s strong (but seemingly not strong enough) efficacy leaves more room for Lilly’s next-generation obesity drug, retatrutide. Moreover, earlier this week, the Food and Drug Administration said supply issues for Zepbound were finally resolved, a situation that should in theory shut down the market for the compounded version of the drug by early 2025. That could force people to shift onto either Zepbound or Wegovy. Yet today’s stock drop also reflects a bevy of issues weighing on Novo’s future. Under the Inflation Reduction Act, Medicare is empowered to negotiate prices on certain drugs, and semaglutide is widely expected to be on its wish list for 2025 (negotiated prices wouldn’t kick in until 2027). And generics could be coming in the early 2030s, Bloomberg Intelligence noted Friday morning. Between those two issues, “the underwhelming result will likely pressure consensus, which sees the asset driving almost 20% of Novo’s sales in 2030,” Bloomberg Intelligence analysts said following the news. That will put added scrutiny on another nascent product, amycretin, which still is only in the early stages of clinical trials, they noted. Investors will no doubt continue to parse each scrap of data that comes out from companies developing obesity drugs to understand who will reap the most benefits from a market expected to be worth $130 billion in the next five years. But as stock prices fluctuate, it’s important to remember who the real winners should be: the tens of millions of Americans with obesity and related chronic health problems who need and deserve affordable treatments. (Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry.) Copy 29/12/2024 10

“The air traffic control tower, the departure lounge — just a few metres from where we were — and the runway were damaged,” Tedros Adhanom Ghebreyesus said on the social media platform X. He added that he and UN colleagues were safe. “We will need to wait for the damage to the airport to be repaired before we can leave,” he said. UN spokesperson Stephanie Tremblay later said the injured person was with the UN Humanitarian Air Service. Our mission to negotiate the release of @UN staff detainees and to assess the health and humanitarian situation in #Yemen concluded today. We continue to call for the detainees' immediate release. As we were about to board our flight from Sana’a, about two hours ago, the airport... pic.twitter.com/riZayWHkvf — Tedros Adhanom Ghebreyesus (@DrTedros) December 26, 2024 Israel’s army later told The Associated Press it was not aware that the WHO chief was at the location in Yemen. The Israeli strikes followed several days of Houthi launches setting off sirens in Israel. The Israeli military in a statement said it attacked infrastructure used by the Iran-backed Houthis at the international airport in Sanaa and ports in Hodeida, Al-Salif and Ras Qantib, along with power stations, asserting they were used to smuggle in Iranian weapons and for the entry of senior Iranian officials. Israel’s military added it had “capabilities to strike very far from Israel’s territory — precisely, powerfully, and repetitively”. The strikes, carried out over 1,000 miles from Jerusalem, came a day after Prime Minister Benjamin Netanyahu said “the Houthis, too, will learn what Hamas and Hezbollah and Assad’s regime and others learned” as his military has battled those more powerful proxies of Iran. The Houthi-controlled satellite channel al-Masirah reported multiple deaths and showed broken windows, collapsed ceilings and a bloodstained floor and vehicle. Iran’s foreign ministry condemned the strikes. The US military has also targeted the Houthis in recent days. The UN has said the targeted ports are important entry points for humanitarian aid for Yemen, the poorest Arab nation that plunged into a civil war in 2014. Over the weekend, 16 people were wounded when a Houthi missile hit a playground in the Israeli city of Tel Aviv, while other missiles and drones have been shot down. Last week, Israeli jets struck Sanaa and Hodeida, killing nine people, calling it a response to previous Houthi attacks. The Houthis also have been targeting shipping on the Red Sea corridor in what it says is an act of solidarity with Palestinians in Gaza. The UN Security Council has an emergency meeting on Monday in response to an Israeli request that it condemn the Houthi attacks and Iran for supplying them with weapons.Luigi Mangione pleads not guilty to murder and weapons charges in UnitedHealthcare CEO's death

Dunn with 28 and Carnegie with 24 highlight No. 13 Georgia Tech women's 100-61 rout of PittsburghIsraeli air strikes on Yemen airport ‘were metres from WHO chief’Israeli attorney general orders probe into report that alleged Netanyahu's wife harassed opponents